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The use of genetically modified organisms (GMOs),
also called living modified organisms (LMOs), genetic
engineered organisms (GEOs), transgenics, or products
of recombinant DNA technologies (Kinderlerer, 2008;
McHughen & Smyth, 2008) is regulated in the majority
of countries around the world (Keese, 2013). Starting in
the late 1970s, countries began to develop provisions to
establish national biosafety regulatory systems to ensure
the safe use of GMOs (Cantley, 2007; Kinderlerer,
2008; Tribe, 2012). For instance, in 1976, the US
National Institutes of Health Recombinant DNA Advi-
sory Committee published the first set of guidelines
governing the safe conduct of recombinant DNA
research, and in 1986 the first national biotechnology-
specific legislation (The Gene Technology Act) was
adopted by Denmark (Cantley, 2007).
The interest to establish national biosafety regula-
tory systems is a direct result of the country’s vision and
policy related to the role of the use of GMOs within its
territory. In most developing countries, however, the
establishment of national biosafety regulatory systems
was an end product of the ratification and entry into
force of the Cartagena Protocol on Biosafety (CPB) to
the Convention of Biological Diversity (McLean, Foley,
& Pehu, 2012). The CPB is an international agreement
that “aims to ensure the safe handling, transport, and use
of LMOs resulting from modern biotechnology that may
have adverse effects on biological diversity, taking also
into account risks to human health” (Secretariat of the
Convention on Biological Diversity, 2000). Thus, over
the last decade and more, developing countries have
received international assistance through numerous
capacity-building initiatives to develop or implement
biosafety regulatory systems (Johnston, Mongagle,
Green, & Mackenzie, 2008) as a means to implementing
the CPB. To date, however, most developing countries
still lack biosafety regulatory systems due to the lack of
institutional capacities and professional expertise in sci-
entific, technical, and legal disciplines for exercising
regulatory oversight (Pertry et al., 2014). Further, the
lack of appropriate coordination and harmonization
across regulatory authorities within individual develop-
ing countries is slowing down GMO decision-making
processes (Adenle, 2011, as cited by Araya-Quesada,
Craig, & Ripandelli, 2012).
There is no best model for building a biosafety regu-
latory system because varying national priorities and
interests by necessity influence each system. However,
specific elements are commonly considered when build-
ing a biosafety regulatory system (Keese, 2013; McLean
et al., 2012; United Nations Environment Programme
[UNEP], 2005). The first step is usually the develop-
ment of a legal framework (Keese, 2013; McLean et al.,
2012; UNEP, 2005). This framework includes the adop-
tion of a country’s policy and legal instruments, such as
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work is put into practice by creating an administrative
system, which ensures that procedures and tools are in
place to support decision-making (Keese, 2013). The
establishment of an administrative system involves the
development of administrative procedures and tools for
the lodgement and processing of applications and the
making of each eventual regulatory decision. Finally, for
the functioning of a biosafety regulatory system, a com-
bination of human resources that have a biosafety tech-
nical background (including experience and
qualifications in modern biotechnology and risk assess-
ment), a legal competency in drafting and implementing
legislation and hands-on experience in administrative
procedures is required in each regulatory authority.
As expected, there is no “one-size-fits-all” approach
to biosafety capacity building for developing countries,
and understanding the specific country context (limita-
tions and priorities) is the basis for any success from
capacity-building assistance (Araya-Quesada, Degrassi,
Ripandelli, & Craig, 2010; Johnston et al., 2008;
McLean et al., 2012).
In order for a country to be able to regulate the use
of GMOs within its territory, it should have experience
in processing applications and making decisions. How-
ever, these two activities are not the only factors that
measure the degree of biosafety expertise in a country: a
country can only truly generate indigenous regulatory
experience through practice, and by utilizing key techni-
cal and scientific information resources (Araya-Quesada
et al., 2012). As such, an operational GMO authoriza-
tion process is a good indication of regulatory compe-
tency and maturity.
The first authorizations regulating the use of GMOs
in Latin America and the Caribbean (LAC region) were
made during the 1990s by Argentina (ARG),1 Brazil
Figure 1. LAC countries with GMOs authorized for various purposes.
Note. Data compiled from Rodriguez (2016), Azurdia (2015), F. Tutillo (personal communication 2015), ISAAA (2015), MAGyP 
(2015), MCTI (2014, 2015), SENAVE (2015), USDA (2015a, 2015b, 2015c, 2015d), Araya et al. (2012), Comision Nacional de 
Bioseguridad para los Organismos Geneticamente Modificados (2012); CONARGEM (2005), SAG (1997, 2013), and Fermin et al. 
(2004, 2010). Maps not to scale. Categories:     Countries with GMOs under development in laboratory and/or glasshouse facilities 
(contained use);     Countries where CFTs of GMOs have been authorized (confined use);     Countries with both GMOs under devel-
opment in laboratory and glasshouse facilities and authorized CFTs;    Countries where the commercial-scale cultivation of GM crops 
has been authorized (unconfined use);    Countries where the importation of GMO or their derived products has been authorized;
    Countries with GMOs under development in laboratory and glasshouse facilities, authorized CFTs, and where both GMOs for com-
mercial-scale cultivation and importation has been authorized;    No information found; and     Country not part of the study.Rosado & Craig — Biosafety Regulatory Systems Overseeing the Use of GMOs in the LAC Region
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(HND), Mexico (MEX), and Uruguay (URY). To date,
11 countries of the LAC region, including the aforemen-
tioned countries and Bolivia (BOL), Colombia (COL),
Cuba (CUB), and Paraguay (PRY), have commercially
cultivated GM crops (International Service for the
Acquisition of Agribiotech Applications [ISAAA],
2015; Figure 1). However, the degree of biosafety
expertise available in the LAC region is quite diverse
(Araya-Quesada et al., 2012). Some countries have
operational biosafety regulatory systems and greater
experience in authorizing the use of GMOs for multiple
purposes, while others have little—or are yet to
gain—experience with GMO authorization, as the
majority of the latter are still lacking the legal frame-
work that underpin a biosafety regulatory system.
Between 2009 and 2011, Araya-Quesada et al.
(2012) undertook an email-based stakeholder consulta-
tion of more than 300 people intimately involved in bio-
safety and/or biotechnology in the LAC region. The
study indicated that 19 countries had experience in pro-
cessing applications and making decisions concerning
the use of GMOs. Countries were categorized according
to experience gained in authorizing four key types of
GMOs use (regulatory activities). These four types were
divided into two broad categories:
1. Research and development (R&D)
• contained use (laboratory/glasshouse research),
• confined use (confined field trials [CFTs]),
2. Commercial purposes
• unconfined use (commercial cultivation), and
• importation of GMOs or their derived products for
food, feed, or processing purposes (FFPs).
Using the results of Araya-Quesada et al. (2012) as a
baseline, the present study sought to provide an update
of the progress, if any, made by countries in the LAC
region in authorizing these four types of GMO use. The
present study considered countries to have an opera-
tional biosafety regulatory system if they have experi-
ence processing applications and making decisions in all
four regulatory activities. Further, specific elements for
building biosafety regulatory systems are described,
with examples from operational LAC national systems
and common limitations identified for building a bio-
safety regulatory system in countries with little, if any,
experience in the authorization of the use of GMOs.
Finally, the present study proposes key considerations
for possible capacity-building assistance in the region.
Operational Biosafety Regulatory Systems: 
Experience in the Authorization of the Use 
of GMOs for Various Purposes
Research and Development (R&D)
Contained Use. Ecuador (ECU), PRY, and Venezuela
(VEN) joined the list of 20 LAC countries (Figure 2) in
which GMO research is authorized in laboratory and
glasshouse facilities. In 2012, ECU’s Polytechnic Supe-
rior School of the Coast (ESPOL), a public university,
began developing GM bananas resistant to black siga-
toka, a leaf-spot disease caused by the ascomycete fun-
gus Mycosphaerella fijiensis. These GM plants,
however, remain in containment facilities since ECU’s
biosafety regulatory system prohibits field trials and
commercial-scale cultivation of GM crops (US Depart-
ment of Agriculture [USDA], 2015a). With the enact-
ment of the ECU’s Constitution (2008), the government
has declared the country to be free of GM crops and
seeds (Article 401). In fact, Article 401 also states that
GM crops and seeds may enter into the ECU’s territory
only under exceptional conditions (applications can be
submitted and processed) should these GMOs be of
national interest according to the Presidency of the
Republic and approved by the National Assembly. Cur-
rently there are initiatives to amend Article 401 of the
Constitution in order to remove the prohibition to use
GM crops and seeds (F. Tutillo, personal communica-
tion, 2015). Similarly in VEN, the University of the
Andes (ULA), in collaboration with Cornell University,
has been developing local GM papaya varieties resistant
to ringspot virus since 1993 (Fermin et al., 2004), but
the products of this research also have yet to reach the
market due to the current biosafety regulatory system in
VEN prohibiting the commercial cultivation of GM
crops. With the recent enactment of VEN’s Law of
Seeds (2015), the production, import, commercializa-
tion, propagation, and use of GM seeds are prohibited in
VEN’s territory. In contrast, since 2013, PRY’s Plant
Health Inspection Service (SENAVE) has authorized
nine GM crop events for research purposes: one GM
maize (Organisation for Economic Co-operation and
Development [OECD] Unique Identifier.2 MON-89034-
3 × DAS-01507-1 × MON00603-6 × DAS-40278-9);
1. Official ISO 3166-1 alpha-3 three-letter country codes (see 
http://unstats.un.org/unsd/tradekb/Knowledgebase/Country-
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MON-15985-7); and six GM soya beans (MON-87708-
9 × MON-89788-1, DAS-44406-6, DAS-81419-2 ×
DAS-44406-6, ACS-GM006-4, MST-FG072-2 and
MST-FG072-2 × ACS-GM006-4; SENAVE, 2015).
Confined Use
There are now 17 countries in the LAC region that have
authorized CFTs of GM plants (Figure 2). New approv-
als for CFTs were authorized in Guatemala (GTM) and
VEN. With respect to the latter two countries, in 2004,
the Ministry of Agriculture, Livestock, and Food in
GTM (MAGA) have approved CFTs of GM maize
(MON-00810-6) and GM cotton (ACS-GH001-3); and
in 2012, MAGA approved CFTs for an additional GM
maize event (DAS-01507-1; Azurdia, 2015; USDA,
2015b). In 2001, ULA obtained a special permit from
VEN’s Ministry of Health to undertake a CFT of their
GM papaya (Fermin, Castro, & Tennant, 2010). To date,
none of these products are yet being produced commer-
cially, as both countries still prohibit the commercial use
of GM crops within their territories. The GTM regula-
tory system does not allow placing GM products on its
market; the only permitted use is the propagation of GM
seeds for export purposes.
Concerning CFTs of GM animals, in 2014 BRA’s
National Biosafety Council approved CFTs of GM mos-
quitoes to determine their efficacy in the control of den-
gue fever (Ministerio da Ciencia, Tecnologia e Inovacao
[MCTI], 2014). BRA and Panama (PAN) are the only
countries in the LAC region to have authorized CFTs of
GM animals, with PAN approving GM salmon and GM
mosquitoes, while BRA has approved only the latter
(Araya-Quesada et al., 2012).
To date, R&D of GMOs is conducted in most Latin
American countries (18) as opposed to Caribbean coun-
tries (three; Figure 2). In the Latin America sub-region,
13 countries have carried out activities with GMOs in
2. A Unique Identifier is a nine-digit alphanumeric code that is 
given to each transgenic plant that is approved for commer-
cial use, including planting and food or feed use (OECD, 
2004).
Figure 2. LAC countries with GMOs under R&D.
Note. Data compiled from Rodriguez (2016), Azurdia (2015), SENAVE (2015), USDA (2015a, 2015b, 2015c, 2015d), Araya et al. 
(2012), and Fermin et al. (2004, 2010). Maps not to scale. Categories:    Countries with GMOs under development in laboratory and/
or glasshouse facilities (contained use);    Countries where CFTs of GMOs have been authorized (confined use);    Countries with 
both GMOs under development in laboratory and glasshouse facilities and authorized CFTs;    No information found; and    Country 
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Figure 2a). ECU, Guyana (GUY), Nicaragua (NIC), and
Peru (PER) have only carried out activities with GMOs
in laboratory and/or glasshouse facilities (red; Figure
2a). In fact, similar to ECU, GMO R&D in PER remains
in containment facilities due to PER’s biosafety regula-
tory system prohibiting CFTs and commercial cultiva-
tion of GMOs. With the enactment of the moratorium
law, PER prohibits CFTs and the commercial cultivation
of GMOs for a period of 10 years (2011-2021). In the
case of GUY, the country does not have a biosafety legal
framework in place to oversee the development of
GMOs in CFTs. Further, NIC has had a biosafety law in
place since 2010 to regulate the use of GMOs, but to
date its National Commission of Risk Analysis of
GMOs (CONARGEM) has yet to approve any GMO for
field testing (USDA, 2015c). Finally, BOL’s regulatory
authority has not received any request for GMO use in
containment (Rodriguez, 2016), however, BOL has
approved the field testing of GMOs developed outside
its territory (yellow; Figure 2). With respect to the
Caribbean sub-region, there are a few countries such as
CUB, Jamaica (JAM), and Trinidad and Tobago (TTO)
that have conducted activities with GMOs for contained
and confined use (orange; Figure 2b). No information
was found for the remaining 10 Caribbean countries
(white; Figure 2b) and there is a strong likelihood that
the majority of them are not carrying out activities with
GMOs under R&D.
Commercial Purposes
Unconfined Use. In the LAC region, the main GM
crops authorized for commercial cultivation are soya
bean, maize, and cotton. Overall, GM crops are author-
ized for commercial cultivation in more Latin American
countries (11) than in Caribbean countries (one: CUB;
Figure 1). CHL, CRI, and PAN joined the list of coun-
tries (Figure 1) in which the commercial cultivation of
GM crops has been authorized. The regulatory systems
of CHL and CRI do not allow the placing of GM prod-
ucts on their markets, although they have both approved
the propagation of GM seeds for export purposes. Since
2012, PAN has begun authorizing the commercial culti-
vation of GM crops, beginning with GM maize DAS-
01507-1 (Comision Nacional de Bioseguridad para los
Organismos Geneticamente Modificados, 2012). In
addition, three new GM crops have been authorized for
commercial cultivation in the region: GM eucalyptus
and GM bean in BRA (MCTI, 2015) and GM potato in
ARG (Ministerio de Agricultura, Ganaderia y Pesca
[MAGyP], 2015).
Importation of GMOs or Their Derived Products for
FFPs. To date, 13 countries in the study region have
authorized the importation of GMOs or their derived
products for FFPs (Figure 1). The importation of GMOs
or their derived products for FFPs is authorized in more
Latin American countries (12) than Caribbean ones
(CUB only). Three countries (CHL, ECU, and NIC)
have recently joined the list of LAC countries that have
issued such authorizations. NIC has approved the import
of 15 different events of GM maize (CONARGEM,
2005), while CHL has approved the import of GM
maize MON-00810-6 (Servicio Agricola y Ganadero
[SAG], 1997) and GM soya bean MON-89788-1 (SAG,
2013), each for use as animal feed only. Further, ECU
has approved the import of food products from GM
maize, soya bean, and tomato (F. Tutillo, personal com-
munication, 2015).
Overall, countries which have authorized GMOs for
commercial purposes are mainly located in the Latin
America sub-region (Figure 1). In this sub-region, nine
countries have authorized GMOs for both commercial
cultivation and import (green and BOL; Figure 1a).
ECU, GTM, and NIC have only authorized the importa-
tion of GMOs or their derived products for FFPs (black
dots; Figure 1a). In fact, as previously mentioned, ECU
prohibits the commercial cultivation of GM crops while
GTM and NIC both have biosafety legal frameworks in
place but do not yet have an operational administrative
system to handle applications for commercial cultiva-
tion. Further, CRI and PAN have authorized GM crops
for only commercial cultivation (black dashes; Figure
1a). In 2010, PAN’s National Commission of Biosafety
for GMOs received a request for the importation of GM
rice for FFPs, but as of 2015 this was still under review
(USDA, 2015d). Further, CRI’s biosafety regulatory
system prohibits the importation of GMOs or their
derived products for domestic consumption. Moving to
the Caribbean sub-region, CUB is the only country that
has authorized the use of GMOs for commercial cultiva-
tion and import (green; Figure 1b). Further, no informa-
tion was found in this respect for the remaining
Caribbean countries (white, JAM and TTO; Figure 1b);
in fact, these countries do not have a biosafety regula-
tory framework in place to oversee activities with
GMOs for commercial cultivation nor import.
In conclusion, our study shows that, since the report
by Araya-Quesada et al. (2012), an additional eight
Latin American countries (CHL, CRI, ECU, GTM, NIC,Rosado & Craig — Biosafety Regulatory Systems Overseeing the Use of GMOs in the LAC Region
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authorization of GMO use for various purposes.
Together this means that 64% (21) of the countries in the
LAC region now have experience in regulating GMOs
(Figure 1). Of these, nine countries have operational
biosafety regulatory system with experience authorizing
the use of GMOs in all four regulatory activities (green;
Figure 1). CHL and PRY joined ARG, BRA, COL,
CUB, HND, MEX, and URY in demonstrating experi-
ence in all four of the key types of the regulatory activi-
ties of interest.
Our study indicates that the majority of LAC coun-
tries (24), mainly those in the Caribbean sub-region, do
not have the full complement of GMO regulatory expe-
rience, ranging from none to three of the four key types
of regulatory activities. Countries with experience in
three of the four regulatory activities are CRI, GTM,
and PAN (CRI and PAN have yet to authorize GMO
imports for FFPs, and GTM has no regulatory experi-
ence with unconfined GMO use). Notably, though previ-
ously included in the group of countries with experience
in three regulatory activities (Araya-Quesada et al.,
2012), BOL now has a restrictive law that prohibits
CFTs and commercial cultivation of GMOs. With the
enactment of the Mother Earth Framework Law in 2012,
BOL specifically prohibits the import, production, and
commercialization of GM seeds and requires measures
for the gradual elimination of any previously approved
GM seed. In addition, eight countries have experience in
one or two types of regulatory activities (two types:
ECU, El Salvador [SLV], JAM, NIC, TTO, and VEN;
and one type only: GUY and PER). Finally, no informa-
tion was found for 10 countries located in the Caribbean
sub-region (Antigua and Barbuda [ATG], Bahamas
[BHS], Barbados [BRB], Dominican Republic [DOM],
Dominica [DMA], Grenada [GRD], Haiti [HTI], Saint
Lucia [LCA], Saint Kitts and Nevis [KNA], and Saint
Vincent and the Grenadines [VCT]; white; Figure 1) and
for two Latin American countries (Belize [BLZ] and
Suriname [SUR]). In fact, these 12 countries have yet to
acquire experience in authorizing GMOs for any use at
all and are all faced with common limitations in the con-
struction of national biosafety regulatory systems at
both the legal and administrative levels. There is also an
apparent insufficiency of trained human resources to
process applications and make decisions in these coun-
tries.
Specific Elements for Building Biosafety 
Regulatory Systems
Development of Biosafety Legal Framework
Countries that lack biosafety legal frameworks initially
tend to prepare a biosafety policy, which outlines their
positions concerning the use of GMOs; the scope and
functions of the regulatory authority(s); and the role of
stakeholders, including other country departments and
agencies (Keese, 2013). This policy is the basis for the
development of specific legislation and regulations
(McLean, Frederick, Traynor, Cohen, & Komen, 2003;
UNEP, 2005). Developing biosafety legislation may
involve the amendment of pre-existing national legisla-
tion or the enactment of new laws (Keese, 2013). Some
countries only enact regulations such as decrees and use
resolutions to serve as the main legal instruments to reg-
ulate the use of GMOs in the absence of specific bio-
safety legislation (Table 1). Once the biosafety
legislative framework is established, a country can
Table 1. Main legal instrument in LAC countries with experience in all four biosafety regulatory activities.
Country Main legal instrument
Type of 
instrument
Year of 
enactment
ARG Resolucion MAGYP 763/2011 Regulation 2011
BRA Lei 11.105 Law 2005
CHL Resolucion No.1523 establece normas para la internacion e introduccion al medio 
ambiente de organismos vegetales vivos modificados de propagacion
Regulation 2001
COL Ley 740 por medio de la cual se aprueba el Protocolo de Cartagena sobre Seguridad de la 
Biotecnologia del Convenio sobre la Diversidad Biologica
Law 2002
CUB Decreto-Ley 190 De la seguridad biologica Law 1999
HND Reglamento de bioseguridad con enfasis en plantas transgenicas Regulation 2001
MEX Ley de bioseguridad de los organismos vivos modificados Law 2005
PRY Decreto No.9699 por el cual se crea la Comision Nacional de Bioseguridad Agropecuaria 
y Forestal (CONBIO)
Regulation 2012
URY Decreto 335/008. Dictense normas relativas a bioseguridad de vegetales y sus partes 
geneticamente modificadas y deroganse los Decretos 249/000 y 37/007
Regulation 2008Rosado & Craig — Biosafety Regulatory Systems Overseeing the Use of GMOs in the LAC Region
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ment the legislation. In the LAC region, countries with
operational biosafety regulatory systems have been
enacting new laws and regulations since the 1990s.
Table 1 lists the main current legal instrument in specific
LAC countries used to regulate GMO use. Countries
such as ARG, BRA, CHL, MEX, PRY, and URY have
had biosafety legal instruments since the 1990s, how-
ever, these instruments have since been modified to
become the instruments indicated in Table 1.
It is important to note that the elaboration of policy,
legislation, and regulations must be consistent with
other biosafety-related instruments, such as national
legal instruments and international obligations, includ-
ing treaties and agreements (e.g., CPB to the Conven-
tion on Biological Diversity and the International Plant
Protection Convention) and relevant international obli-
gations directed by the Codex Alimentarius Commis-
sion, International Organization for Standardization,
World Organization for Animal Health and the World
Trade Organization (Keese, 2013; McLean et al., 2003).
Based on their biosafety legal framework, countries
usually nominate and delegate functions to different reg-
ulatory authorities (e.g., specialized Ministries, agen-
cies, and/or advisory bodies) to implement the biosafety
regulatory system and also to designate the final deci-
sion-maker(s), such as the President of a Board, a Min-
ister, an Administrator, etc. In some cases, the scope of
the decision-maker varies depending on the purpose of
the GMO use. Thus, some legislation states that the
Minister of Agriculture is the decision-maker for appli-
cations for the use of GMOs for agricultural purposes,
while the Minister of Environment is the decision-
maker for environment purposes, and the Minister of
Health is the decision-maker for GMOs or their derived
products for FFPs. Some countries however, prefer to
designate only one overall decision-maker regardless of
the sector of eventual authorized use (e.g., ARG, BRA,
CHL, CUB, HND, PRY, URY).
Establishment of Administrative Systems
Countries need an administrative system of procedures
and tools for the lodgement and processing of applica-
tions and for making the final decision. Around the
world, numerous reviews have documented a variety of
established regulatory approaches to evaluate the risks
associated with the use of GMOs (McHughen & Smyth,
2008). Furthermore, key elements such as appropriate
mechanisms for risk assessment, risk management, and
risk communication are well established (McLean et al.,
2012). The central role of risk assessment in regulatory
decision-making is well-recognized and is evident from
the large amount of guidance material and training
courses available (Keese, 2013).
In order to facilitate the lodgement of applications,
regulatory authorities must first make application forms
available, and usually directly from their website. For
example, in the LAC region, application forms3 are
available on the websites of ARG’s Ministry of Agroin-
dustry and URY’s Biosafety National Cabinet (GNBio).
According to these two examples, and supported by
Keese (2013), a model application form for commercial
use will request the following information:
• the identity and address of the applicant,
• the type of licence/permit authorization applied for,
• the intended use of the GMO,
• a scientific and technical description of the GMO, 
• proposed conditions to safely manage the activity
with the GMO, and
• any previously granted approval(s) of the same
GMO use by a foreign regulatory authority/ies.
Application forms for contained and confined use can
also request information such as the technical staff
responsible for carrying out the proposed activities
involving the GMOs, and the facility to be used or the
location for which the activity with the GMO is
intended. Moreover, additional forms and requirements
may be developed for the collection of specific informa-
tion and made available on the regulatory authority
website. For instance, requirements of risk assessments4
are available on the website of HND’s National Agricul-
ture Health Service (SENASA) and CHL’s Agricultural
and Livestock Service (SAG). In addition, regulatory
authorities, such as those from URY5 also describe the
payment process for application fees (if applicable).
3. To download the application forms from ARG and URY, see: 
http://www.agroindustria.gob.ar/sitio/areas/biotecnologia/
solicitudes/ and http://www.mgap.gub.uy/unidad-ejecutora/
direccion-general-de-control-de-la-inocuidad-alimentario/
bioseguridad/procedimientodeautorizacion, respectively.
4. To download the guidance for risk assessment from CHL and 
HND, see http://www.sag.cl/ambitos-de-accion/organismos-
geneticamente-modificados-ogm/1354/procedimientos, and 
http://www.senasa.gob.hn/index.php/sub-direcciones/sub-
direccion-tecnica-de-sanidad-vegetal/depto-de-certificacion-
de-semillas/formato-y-requisitos-cs, respectively.
5. See http://www.mgap.gub.uy/sites/default/files/multimedia/
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the publication of a notice indicating the receipt of each
application (including the description of the GMO and
its intended use) in the country gazette, local newspa-
pers, or regulatory authority website for a specific
period (Keese, 2013). The legislation may require this to
facilitate the inviting of public comments or for legal
notification purposes. ARG’s Ministry of Agroindustry,
MEX’s Inter-secretarial Commission of Biosafety of
GMOs (CIBIOGEM), and URY’s GNBio all publish a
summary of each application received on their respec-
tive websites in order to invite comments from the pub-
lic for a specific period. Other countries, such as CHL,
publish a summary of the application in the official
gazette. It is also common during the application pro-
cess for the applicant to be required to provide informa-
tion that is considered confidential, and thus will
provide reasons for it not to be made public. Some bio-
safety legislation also requires publishing a summary of
the results of the risk assessment for public comments or
legal notification purposes (e.g., ARG, BRA, COL,
HND, MEX, and URY). COL (J. Bocanegra, personal
communication, 2015) and HND (C. Almendares, per-
sonal communication, 2015) only publish a summary of
the risk assessment on the international node of the Bio-
safety Clearing-House (BCH).6
Regarding the processing of applications, it is com-
mon for biosafety legislation to require the establish-
ment of a Technical Advisory Committee or Council
(TAC) to provide scientific and other technical advice to
the decision-maker. The TAC is usually tasked to under-
take the requisite risk assessment or to review the risk
assessment documents lodged by the applicant. Mem-
bers of the TAC are typically representatives from Min-
istries and agencies of regulatory authorities,
universities, and the private sector, amongst others.
These representatives are mostly full-time employees of
their institutions and, at the same time, ad hoc members
of the TAC. The regularity of committee meetings may
vary depending on the number and type of applications
received. Legislation, for example from ARG, COL, and
MEX, may establish more than one TAC charged to
assess applications according to specific intended uses.
In addition, biosafety legislation can allow the TAC to
seek advice from other national and international
experts in the field or to form sub-committees.
Finally, upon receipt of the application and evalua-
tion by the TAC, the decision-maker may either decide
to approve a license or permit, to refuse it, or to approve
it subject to conditions. Legislation may also require the
establishment and maintenance of a publicly-accessible
register of licenses and permits. In the LAC region, a
public register of licenses and permits is available on the
websites of ARG’s Ministry of Agroindustry, BRA’s
National Biosafety Technical Commission (CTNBio),
COL’s Ministry of Health and Social Protection (MIN-
SALUD), MEX’s CIBIOGEM, and URY’s GNBio.
Moreover, a public register is also available in the inter-
national BCH for the aforementioned countries, includ-
ing HND.
Common Limitations of Biosafety 
Regulatory Systems
Lack of Biosafety Legal Frameworks
Beginning in 2001, the LAC region has received techni-
cal support from the United Nations Environment Pro-
gramme (UNEP), funded by the Global Environment
Facility (GEF), for the development and implementation
of national biosafety frameworks. To date however, 12
countries, principally located in the Caribbean sub-
region, have only progressed to having drafts of their
legal biosafety frameworks, and in some cases, bio-
safety bills (Table 2); these drafts are undergoing revi-
sion in preparation for future enactment. Further, some
countries, such as ATG and KNA, are also developing
regulations to support the implementation of their bio-
safety legislation.
In fact, according to our study, the majority of these
countries have yet to gain GMO regulatory experience.
Specifically, the Caribbean sub-region comprises more
countries (10) in the LAC region with no GMO regula-
tory experience than the Latin America sub-region
(BLZ and SUR only). Amongst the Caribbean countries
with no GMO regulatory experience, only DOM and
KNA have recently promulgated biosafety laws (Table
3). The Caribbean sub-region also includes two coun-
tries, GUY and TTO, with experience in one and two
regulatory activities, respectively. In fact, these two
countries make use of plant quarantine import permits to
authorize the importation and introduction of GMOs.
However, none of these countries have an operational
biosafety regulatory framework in place to oversee the
production or release of GMOs. This therefore repre-
sents a serious impediment to activities for R&D in both
6. See https://bch.cbd.int website for more information about the 
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level (USDA, 2015e).
Clearly, these LAC countries will continue to face a
de facto moratorium regarding the importation and use
of GMOs until they have a biosafety regulatory system
in place. The lack of legislative instruments can result in
the complete prohibition of the use of GMOs until such
time that there is sufficient political will to resolve the
situation (Obonyo, Nfor, & Uzochukwu, 2011). Due to
the absence of appropriate legislation, there are pro-
tracted delays in assessing GM products, and by exten-
sion, any eventual authorization. Such delays, caused by
the lack of judicial and political decisions, can result in
undesirable situations, such as the illegal planting of
GM crops (Pelaez, 2009, as cited by Obonyo et al.,
2011). For instance, there has been illegal importation of
GMOs into ATG with GM seeds confiscated by the
Plant Protection Agency (Black-Layne, 2016).
Absence of Administrative Systems
The majority of the LAC countries with GMO regula-
tory experience in less than four key types of GMO use,
principally in the Caribbean sub-region, require the
adoption of administrative systems for the effective
functioning of their biosafety regulatory systems such
that applications for GMO use can be processed and
regulatory decisions made. The majority of Latin Amer-
ican countries and a few Caribbean countries have pro-
mulgated biosafety legal frameworks but have yet to
implement an operative administrative system to handle
applications for all four key types of GMO use (Table
3). Even though BOL, ECU, PER, and VEN have legal
instruments in place, they also have restricted regula-
tions that prohibit CFTs and commercial cultivation in
their territories, and thus no specific administrative pro-
cedures are required for those regulatory activities.
Some GMO uses, such as research activities in con-
tained use, are however permitted in these four coun-
tries, and the importation of GMOs or derived products
for FFPs is allowed in BOL, ECU and PER. These latter
GMO regulatory activities will require administrative
procedures to be developed. The majority of countries in
the LAC region have not yet developed procedures for
the lodgement, processing, and decision-making con-
cerning applications, nor have they developed tools
(e.g., application forms, guidance documents, standard
operating procedures, etc.) that lay the basis for an
effective administrative system.
Currently, a few LAC countries (ECU, SLV, GTM,
PAN, PER, and KNA) are developing drafts of their
administrative systems under their respective UNEP-
GEF National Biosafety Framework Projects. However,
due to the recent nature of their legislation enactment,
DOM (M. Hernandez, personal communication, 2015)
Table 2. Description of legal framework for those LAC countries without a promulgated biosafety legal framework.
Country Current biosafety legal status Draft regulations
ATG Latest 2015 draft Bill ready for finalization by the Office of Parliamentary 
Drafting and will be subject to another consultation
Prepared in 2015: i) import, export, and 
transit; ii) environmental release; iii) 
contained use; and, iv) labelling
BHS Have only a draft national biosafety framework completed in 2008 None
BRB Draft Bill prepared in 2008 and still undergoing review None
BLZ Draft Bill prepared in 2006 and still undergoing review None
DMA Latest draft Bill was finalized in 2016 and it is waiting for approval by the House 
of Assembly so it can be enacted
None
GRD Biosafety Policy was approved in 2014. Latest 2014 draft Bill is ready for 
finalization by the Parliamentary drafter from the Ministry of Legal Affairs, after 
which approval for introduction will be sought
None
GUY Latest draft of Biosafety Bill was prepared in 2015 and upon which a public 
consultation is currently underway
None
HTI Have only a draft national biosafety framework which was completed in 2008 None
LCA Latest draft of Biosafety Bill prepared in 2014 and currently undergoing further 
re-drafting. Both the biosafety legislation and policy are still in draft form and 
have yet to go before Parliament
None
VCT Latest draft of Biosafety Bill prepared in 2015 and currently undergoing re-
drafting
None
SUR No draft bill None
TTO Have a draft national biosafety framework which was completed in 2015 NoneRosado & Craig — Biosafety Regulatory Systems Overseeing the Use of GMOs in the LAC Region
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have not yet developed specific regulations for the
effective implementation of their legislation. Both coun-
tries are in the early stages of drafting regulations for the
implementation of administrative systems. In general,
the lack of administrative systems triggers delays and
denials in the acceptance and processing of applications.
For example, in the case of DOM, in 2006 the Regula-
tory Authority, the former Secretary of Environment and
Natural Resources (now Ministry of Environment and
Natural Resources), denied the import of GM zebra fish
(GloFish®), citing the lack of regulations regarding
decision-making (Secretaria de Estado de Medio Ambi-
ente y Recursos Naturales, 2006). Other countries, such
as PER, do not have specific regulations to help imple-
ment biosafety legislation and handle applications (S.
Pastor, personal communication, 2015). In addition, nei-
ther GTM (C. Azurdia, personal communication, 2015)
nor DOM (M. Hernandez, personal communication,
2015) offers official risk assessment guidance to support
the processing of applications.
Conclusions
Our results demonstrate since Araya-Quesada et al.
(2012), the establishment of biosafety regulatory sys-
tems and the degree of GMO regulatory experience are
still diverse across the LAC region. Notably, there is a
big difference in terms of regulatory experience in pro-
cessing applications and making decisions between
Latin American and Caribbean countries. The Latin
America sub-region is home to eight countries with
operational biosafety regulatory systems that have accu-
mulated extensive experience in regulating GMOs for a
multitude of diverse purposes. In the Caribbean sub-
region, however, CUB is the only country with a wide
experience in regulating the use of GMOs. The lack of
biosafety legal frameworks and the absence of adminis-
trative systems, principally in the Caribbean sub-region,
Table 3. Current biosafety status of LAC countries with a promulgated biosafety legal framework but without administrative 
procedures for all four biosafety regulatory activities.
Country Main legal instrument Administrative system
BOL Have had biosafety regulations since 1997 (Reglamento sobre bioseguridad) No
CRI Have had a biosafety law since 2006 (Ley No.8537 Ley 740 Aprobacion del 
Protocolo de Cartagena sobre Seguridad de la Biotecnologia del Convenio 
sobre la Diversidad Biologica)
Yes (only for contained, confined and 
unconfined use)
DOM Have a recent biosafety law which was enacted in 2015 No
ECU Have a recent biosafety regulation which was enacted in 2015 (Acuerdo 
No.425 Reformar el titulo VII del libro IV del texto unificado de legislacion 
secundaria del Ministerio del Ambiente)
No. Being developed under the UNEP-
GEF National Biosafety Project
SLV Have had biosafety regulations since 2008 (Decreto No.78. Reglamento 
especial para el manejo seguro de los organismos modificados geneticamente)
No. Being developed under the UNEP-
GEF National Biosafety Project
GTM Have had biosafety regulations since 2006 (Acuerdo Ministerial No.386-2006 
acuerdase establecer los requisitos para la importacion, transporte, manejo 
dentro del pais, establecimiento de experimentos de campo y produccion para 
exportacion de organismos vivos modificados – OVM, para uso agricola)
No. Draft of administrative system was 
developed in 2015 under the UNEP-
GEF National Biosafety Project
KNA Have had a Biosafety Act since 2012 No. Being developed under the UNEP-
GEF Regional Biosafety Project
JAM Have The Plant (Quarantine) Act, 1997 Yes (only for contained and confined 
use)
NIC Have had a biosafety law since 2010 (Ley No.705. Ley sobre prevencion de 
riesgos provenientes de organismos vivos modificados por medio de 
biotecnologia moderna)
No
PAN Have had a biosafety law since 2002 (Ley No.48. Ley que crea la Comision 
Nacional de Bioseguridad para los Organismos Geneticamente Modifcados y 
dicta otras disposiciones)
No. Being developed under the UNEP-
GEF National Biosafety Project
PER Have had a biosafety law since 1999 (Ley No.27104. Ley de prevencion de 
riesgos derivados del uso de la biotecnologia)
No. Being developed under the UNEP-
GEF National Biosafety Project
VEN Have had a biosafety regulation since 2006 (Decreto No.4.334, mediante el 
cual la se dispone que la Comision Nacional de Bioseguridad, como organism 
tecnico-cientifico, asesorara al Ejecutivo Nacional en las actividades que en el 
se senalan)
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of LAC countries in establishing their biosafety regula-
tory systems. Therefore, these limitations create a de
facto moratorium regarding the use of GMOs in such
countries until a biosafety regulatory system is in place.
Clearly, the national priorities and interests of each
country vary the scope of their GMO regulation. Based
on their national biosafety legal framework, countries
indicate the uses of GMOs that are permitted within
their territories. In fact, capacity building assistance is
most effective when provided as phased support, focus-
ing initially on the one or two GMO uses that the coun-
tries are immediately facing (e.g., developing and
implementing administrative procedures for processing
applications and making decisions on limited regulatory
activities, such as importation as a first step, or con-
tained use), and then building upon that to extend to the
full complement of regulated GMO use in accordance
with its biosafety legal framework. 
Our study suggests that capacity-building assistance
in the region is best focused on efforts at the legal and
administrative level. It is worth noting that those few
LAC countries currently with comprehensive and opera-
tional systems have created them with minimal interna-
tional assistance and have expended great efforts to
improve their systems, thus gaining experience process-
ing applications and making decisions, while the
remainder (the majority) of LAC countries still do not
have such systems in place, even after more than 10
years of receiving international technical and financial
assistance from various donors. In fact, many countries,
principally in the Caribbean sub-region, have yet to pro-
mulgate any biosafety legislation. However, further
analysis is needed to investigate the extent to which
insufficient political will is a key factor in the success of
capacity building assistance.
In the LAC region, there are good examples of coun-
tries with competent and mature regulatory systems.
The formation of strategic partnerships between such
countries and others with less experience would greatly
assist the harmonization of regulatory matters (e.g.,
drafting and implementing legislation) and administra-
tive procedures (e.g., operational GMO authorization
processes) in the region. ARG, BRA, CUB, and MEX
are obvious strong candidate countries to lead such stra-
tegic partnerships.
Finally, recognizing that the cohort of personnel
trained in any given capacity building project or
endeavor is subjected to the fluxes of parliamentary
changes, the degree of their training as well as the stabil-
ity of their positions suffer, and thus until the establish-
ment of a bona fide regulatory system is prioritized by
the government and/or society, this phenomenon of
insufficient trained human resources will continue to be
requested in future capacity-building initiatives.
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